Time to response was not associated with sex, age, baseline total IgE, aeroallergen sensitization, atopic background, or autoimmune thyroid disease.<h4>Conclusion</h4>In dermographometer-confirmed, antihistamine-refractory DPU, omalizumab was associated with a rapid clinical remission in almost all patients, typically within 24-48 hours, independent of baseline IgE and common comorbidities. This evidence concerns the gene IGHE and autoimmune thyroid disease.